# Signals Article: Investigating the Putative Target P60484 in Endometrial Cancer
Background
The protein encoded by the putative target P60484 has emerged as a candidate of interest in the study of endometrial cancer, a malignancy that arises from the lining of the uterus and is often associated with hormonal imbalances. Preliminary expression data suggest that P60484 may play a significant role in the tumor biology of endometrial cancer, potentially influencing pathways related to cell proliferation and apoptosis. However, the therapeutic implications of targeting this protein remain largely unexplored, indicating a need for further investigation.Data-mining rationale
To identify novel therapeutic targets for endometrial cancer, we conducted a data-mining analysis utilizing the UniProt database, focusing on reviewed human entries associated with the disease. We cross-referenced these entries against 118 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate P60484 was identified in several expression-profiling studies, yet it currently lacks any registered Phase 1 or higher clinical programs, highlighting a significant gap in its potential clinical application.Why prior analyses may have missed this
Many of the GEO datasets included in our analysis were generated prior to the implementation of modern empirical-Bayes statistical methods, such as limma, which are essential for accurate differential expression analysis. The absence of rigorous multiple-testing corrections in earlier studies may have obscured the significance of P60484’s expression patterns in endometrial cancer. Consequently, the relevance of this candidate may not have been fully appreciated, underscoring the need for a re-analysis of existing data using contemporary statistical methodologies.Reasoning for further validation
To further explore the role of P60484 in endometrial cancer, we propose the following experimental approaches: 1. **Re-analyze the matched GEO datasets** using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to accurately identify differentially expressed genes. 2. **Validate the top differentially-expressed genes** through quantitative PCR (qPCR) in an independent cohort of endometrial cancer samples to confirm the expression patterns observed in the initial analysis. 3. **Check tissue specificity** of P60484 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to evaluate its potential as a selective therapeutic target. 4. **Run pathway analysis** using tools like STRING or OmniPath to contextualize P60484 within relevant biological pathways and networks associated with endometrial cancer. 5. **If validated**, assess the druggability of P60484 through databases such as DGIdb and ChEMBL to explore potential therapeutic compounds that may target this candidate.References
- [UniProt: P60484](https://www.uniprot.org/uniprot/P60484)
- [UniProt: P54278](https://www.uniprot.org/uniprot/P54278)
- [UniProt: P42336](https://www.uniprot.org/uniprot/P42336)
- [UniProt: Q99708](https://www.uniprot.org/uniprot/Q99708)
- [UniProt: O00425](https://www.uniprot.org/uniprot/O00425)
- [GEO Accession: GDS:200269693](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200269693)
- [GEO Accession: GDS:200225956](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200225956)
- [GEO Accession: GDS:200288518](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200288518)
- [GEO Accession: GDS:200203024](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200203024)
- [GEO Accession: GDS:200164724](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200164724)